Purple Biotech Reports Second Quarter 2023 Financial Results

Financial results represent clinical trials progress with recruitment at a pace faster than expected in CM24 Phase 2 studyClinical data from both studies expected in the coming months Cash runway...

Related Keywords

Israel ,Rehovot ,Hamerkaz ,Gil Efron ,Lior Fhima ,Development Expenses ,International Financial Reporting Standards ,Bristol Myers Squibb ,Purple Biotech Ltd ,Exchange Commission ,Owners Of The Company ,Company Contact ,Drug Administration ,Purple Biotech ,Isaac Israel ,Months Ended June ,Administrative Expenses ,Six Months Ended June ,Open Market Sale ,Tumor Associated Antigen ,Looking Statements ,Safe Harbor ,Private Securities Litigation Reform Act ,Annual Report ,Registration Statements ,Unaudited Statements ,Financial Position ,Unaudited Statement ,Comprehensive Loss ,Adjusted Operating ,Adjusted Net ,Markets ,